Increased level of TXNIP and nuclear translocation of TXN is associated with end stage renal disease and development of multiplex renal tumours

Background: End-stage and acquired cystic renal disease (ESRD/ACRD) kidneys are characterized by inflammatory remodelling and multiplex renal cell carcinomas (RCC). Eosinophilic vacuolated tumour (EVT) occurs exclusively in ACRD. The aim of this study was to identify the involvement of thioredoxin-i...

Full description

Saved in:
Bibliographic Details
Main Authors: Beöthe, Tamás (Author) , Docs, Janos (Author) , Kovacs, Gyula (Author) , Peterfi, Lehel (Author)
Format: Article (Journal)
Language:English
Published: 17 July 2024
In: BMC nephrology
Year: 2024, Volume: 25, Pages: 1-7
ISSN:1471-2369
DOI:10.1186/s12882-024-03653-4
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12882-024-03653-4
Get full text
Author Notes:Tamas Beothe, Janos Docs, Gyula Kovacs and Lehel Peterfi
Description
Summary:Background: End-stage and acquired cystic renal disease (ESRD/ACRD) kidneys are characterized by inflammatory remodelling and multiplex renal cell carcinomas (RCC). Eosinophilic vacuolated tumour (EVT) occurs exclusively in ACRD. The aim of this study was to identify the involvement of thioredoxin-interacting protein (TXNIP) and thioredoxin (TXN) in ESRD/ACRD pathology. Methods: Expression of TXNIP and TXN was examined in histological slides of 6 ESRD and 6 ACRD kidneys, precursor lesions and associated tumours as well as of RCCs from the general population by immunohistochemistry. Results: Strong TXNIP expression was seen in epithelial cells, myo-fibroblasts and endothelial cells and weak TXN expression in ESRD/ACRD kidneys and tumours. In ACRD specific EVT and its precursors TXN were translocated into nuclei. Conclusion: The impaired TXNIP/TXN redox homeostasis might be associated with development of multiplex cancer especially of EVT in ESRD/ACRD kidney.
Item Description:Gesehen am 16.12.2024
Physical Description:Online Resource
ISSN:1471-2369
DOI:10.1186/s12882-024-03653-4